WO2013072304A1 - Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4 - Google Patents

Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4 Download PDF

Info

Publication number
WO2013072304A1
WO2013072304A1 PCT/EP2012/072482 EP2012072482W WO2013072304A1 WO 2013072304 A1 WO2013072304 A1 WO 2013072304A1 EP 2012072482 W EP2012072482 W EP 2012072482W WO 2013072304 A1 WO2013072304 A1 WO 2013072304A1
Authority
WO
WIPO (PCT)
Prior art keywords
container
dose
water
pharmaceutical preparation
solution
Prior art date
Application number
PCT/EP2012/072482
Other languages
French (fr)
Inventor
Lorenzo Bellorini
Alberto Bernareggi
Marco Pizzutti
Original Assignee
Altergon S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45315902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013072304(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL16154717.9T priority Critical patent/PL3056187T5/en
Priority to DK12798182.7T priority patent/DK2790638T3/en
Priority to CA2853880A priority patent/CA2853880C/en
Priority to ES12798182.7T priority patent/ES2621009T3/en
Priority to EP16154717.9A priority patent/EP3056187B2/en
Application filed by Altergon S.A. filed Critical Altergon S.A.
Priority to EP12798182.7A priority patent/EP2790638B1/en
Priority to CN201280055960.7A priority patent/CN103987358B/en
Priority to RU2014119151A priority patent/RU2688430C2/en
Priority to US13/814,770 priority patent/US20140179785A1/en
Publication of WO2013072304A1 publication Critical patent/WO2013072304A1/en
Priority to HK15101283.7A priority patent/HK1200692A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Definitions

  • the present invention relates to a pharmaceutical preparation of thyroid hormones T3 and T4.
  • the invention relates to a pharmaceutical preparation of thyroid hormones T3 and T4 in water-alcohol solution, suitable for oral administration and characterised by high physical, chemical and microbiological stability.
  • the invention also relates to the use of said pharmaceutical preparation in the treatment of disorders caused by hormone T3 and/or T4 deficiency.
  • the thyroid hormones triiodothyronine or liothyronine (T3) and tetraiodothyronine or thyroxine (T4) are secreted by the follicular cells of the thyroid gland in response to the pituitary-gland hormone TSH, the production of which is regulated in turn by the hypothalamic hormone T H.
  • TSH pituitary-gland hormone
  • T H hypothalamic hormone
  • the secretion of thyroid hormones follows a circadian rhythm; the highest levels of T3 and T4 are reached during the night and the early hours of the morning.
  • T3 and T4 are essential for the normal body growth of children and for the maturation of the various apparatuses, especially the skeleton, and regulate metabolic activity in the adult, influencing the function of every organ and tissue.
  • T3 and T4 increase oxygen consumption at rest, raising the basal metabolism, the body temperature and the daily calorie requirement. They regulate carbohydrate metabolism, promoting glycogenolysis and gluconeogenesis, and increase the activity of the enzymes involved in glucose oxidation.
  • the thyroid hormones are involved in lipolysis and lipogenesis, regulate protein synthesis, exercising a trophic effect on the muscle, and affect the cardiovascular system.
  • Thyroid hormones are essential to the cardiac function: they increase myocardial contractility (positive inotropic effect), increase the heart rate (positive chronotropic effect) and increase venous return to the heart.
  • the effect of the thyroid hormones is mainly anabolic at low doses, whereas they have a catabolic action at high doses.
  • a treatment based on T3 and/or T4 is required, administered as such or in the form of sodium salts or hydrates.
  • T3 and T4 Treatment with thyroid hormones continues throughout the patient's life, and the posology (dose and frequency of administration) is customized according to the patient's response.
  • the initial dose of T3 and T4 is usually low.
  • the dose is then gradually increased until the clinical evaluation and laboratory tests indicate an optimum response. Selecting the dose is a critical aspect: an under-dose leads to a poor response, while an excessive dose can produce toxic symptoms of hyperthyroidism such as tachycardia, sweating, weight loss, nervousness, diarrhoea, bone resorption due to activation of the osteoclasts, and heart problems.
  • T3 and T4 hormones are on the market in solid form (regular tablets and soft gelatin capsules) and in liquid oral form in drops.
  • This last pharmaceutical form makes the hormones immediately available for gastrointestinal absorption, and usually consists of a solution in a single multi-dose glass container with a dropper.
  • the use of the dropper makes it difficult to measure accurately the volume of solution dispensed, and therefore the dose administered.
  • T4 solution with a concentration of 100 ⁇ g/mL is used, for example, T4 doses of between 3.5 and 200 ⁇ g may be administered. Assuming that each drop (approx.
  • 35 ⁇ .) contains 3.5 ⁇ g of T4, the administration of the maximum dose of 200 ⁇ g requires no less than 57 drops to be dispensed (2 mL). Moreover, the volume of the drops dispensed is not precisely replicable. The use of a dropper may therefore not guarantee the necessary dose accuracy, which is provided by other forms of administration such as tablets or soft capsules available in a variety of doses to allow optimum individual treatments.
  • formulation ingredients for pharmaceutical use with high vapor pressure in general, such as alcohols, or inert gases, such as nitrogen, can act as solvents of the active ingredients present in the finished product or as preservatives, and can also, in synergy with other ingredients present in the pharmaceutical form, promote the physical and chemical stability of the finished product.
  • Volatile organic solvents such as ethanol are used to facilitate the dissolution of hormones T3 and/or T4. Adequate containment of volatile substances is necessary to guarantee the physical and chemical stability of the product. Evaporation of said substances from the formulation through the primary packaging material must be prevented, to avoid a gradual reduction in their concentration over time.
  • Patent application WO2010/086030 discloses a single-dose squeezable container for solutions of T3/T4 hormones, which is made of plastic with a Young's modulus of between 10 and 80 MPa, and in particular of a mixture of polyethylene or polypropylene with ethylene vinyl acetate.
  • said container presents optimum squeezability characteristics which ensure that the solution is completely emptied, it is unable to preserve the chemical and physical stability of the water-alcohol solutions of hormones T3/T4 it contains, causing a loss of alcohol solvent and increasing the quantity of impurities present in it during storage.
  • the purpose of the present invention is therefore to overcome the drawbacks associated with the prior art, in particular the chemical and physical instability of water-alcohol solutions of hormone T3/T4 stored in the containers described in WO2010/086030, while maintaining the convenience and accuracy of dose and administration offered by single-dose squeezable containers.
  • the present invention relates to a single-dose pharmaceutical preparation of thyroid hormones T3 and T4 suitable for oral administration, in ready-for-use packaging consisting of a container prefilled with a water-alcohol solution of hormone T3 and/or T4, said container being selected from:
  • plastic container with a thickness of between 200 and 700 ⁇ , squeezable by manual compression, having a Young's modulus of between 10 and 200 MPa and characterised by multiple layers of plastics suitably selected from polyethylene, ethylene vinyl alcohol copolymer resins, polyvinyl chloride, polyvinylidene chloride, polyvinyl acetate, fluorinated-chlorinated resins, ionomer resins, cyclic olefin copolymers, polyamide, polystyrene, polycarbonate, laminated metals, and in particular aluminium bonded to plastics.
  • plastics suitably selected from polyethylene, ethylene vinyl alcohol copolymer resins, polyvinyl chloride, polyvinylidene chloride, polyvinyl acetate, fluorinated-chlorinated resins, ionomer resins, cyclic olefin copolymers, polyamide, polystyrene, polycarbonate, laminated metals, and in particular aluminiu
  • the sachet consists of a film made of several layers of materials according to the following combinations: polyethylene, aluminium and polyester; polyethylene, aluminium and paper; ionomer resins, aluminium and paper.
  • the sachet also presents oxygen and water vapor permeability preferably between 0.1 and 0.2 cc/m2/day.
  • the water-alcohol solution can contain 1 to 20 g of thyroid hormone T3 and/or 12.5 to 200 g of thyroid hormone T4, ethyl alcohol in quantities preferably ranging between 5 and 30% w/v, glycerol in quantities preferably ranging between 70 and 95% w/v, and water.
  • the pharmaceutical preparation according to the invention contains not less than 95% of the initial ethanol concentration, a T3 and/or T4 content of not less than 95% of the initial concentration, and total impurities (excluding impurity T3 in the single-dose T4 container) ⁇ 2.5% of the initial concentration of active ingredient.
  • the pharmaceutical preparation according to the invention due to its characteristics, guarantees the absence of microbiological contamination, with TAMC (total aerobic microbial count) values ⁇ 100 CFU/g, TYMC (total yeast and mould count) values ⁇ 10 CFU/g, and absence of E. coli, thus being practical to use and not liable to accidental contamination.
  • TAMC total aerobic microbial count
  • TYMC total yeast and mould count
  • the pharmaceutical preparation according to the invention is conveniently used to treat disorders associated with thyroid hormone T3 and/or T4 deficiency.
  • a further aspect of the invention therefore relates to the use of a water- alcohol solution of thyroid hormone T3 and/or T4 in a container as described above, to prepare a medicament for oral administration in the treatment of disorders associated with thyroid hormone T3 and/or T4 deficiency.
  • the container In order to be easily squeezable and ensure complete delivery of its contents, the container must be soft and malleable. This state is usually achieved with the use of low-density polyethylene, polypropylene and sometimes with the addition of suitable "softening” agents such as EVA, which produce "loose” crosslinking.
  • Squeezable containers are characterised by a plastic material having a sufficiently low Young's modulus. The best results have been obtained with plastics characterised by a Young's modulus of less than 200 MPa. It has been demonstrated that when plastic containers with such a Young's modulus are used, the contents are almost completely extracted by a single manual compression.
  • ⁇ ⁇ /1 where ⁇ 1 is the amount by which the length of the object changes and 1 is the original length of the object.
  • Plastics with such a Young's modulus are obtainable by injection molding or blowing.
  • Suitable pharmaceutical-grade plastics can be polyethylene (PE), ethylene vinyl alcohol copolymer resins (EVOH), polyvinyl chloride (PVC), polyvinylidene chloride (PVdC), polyvinyl acetate (PVA), fluorinated- chlorinated resins, ionomer resins, cyclic olefin copolymers (COC), polyamides (PA), polystyrene (PS), polycarbonate (PC), laminated metals such as aluminium bonded to plastics, blends of the materials listed above in variable percentages, or stratifications of the above-mentioned materials of variable thickness.
  • PE polyethylene
  • EVOH ethylene vinyl alcohol copolymer resins
  • PVC polyvinyl chloride
  • PVdC polyvinylidene chloride
  • PVA polyvinyl acetate
  • fluorinated- chlorinated resins ionomer resins
  • ionomer resins cyclic olefin copo
  • the T4 preparation to which the present invention relates proved, in terms of total impurity content, more stable than the solution stored in single- dose primary packaging made of an EVA-PE blend (50%-50%) (Table 2).
  • the experiment was conducted by storing the samples at 50°C for ten days. The values are expressed as percentages of the initial active ingredient content.
  • T4 preparation according to the invention in single-dose packaging proved more chemically stable than similar formulations in multi-dose amber glass bottles present on the market.
  • Table 3 compares the values of the impurities after storage under ICH conditions at 25°C/60% RH for 6 months. The values are expressed as percentages of the active ingredient content.
  • Table 4 compares the values of the impurities in samples stored under ICH conditions at 25°C/60% RH for 6 months. The values are expressed as percentages of the initial active ingredient content.
  • the extractability of the water-alcohol T4 solution from the single- dose LDPE container containing 1.1 mL of solution was evaluated by means of a squeezability test based on successive squeezes to demonstrate the complete, reproducible release of the expected volume of solution, namely 1.0 mL.
  • the test involved a representative population of 60 subjects, matched for gender and age, divided into three groups consisting of 10 males and 10 females aged under 30 years, over 50 years or between 30 and 50 years. The subjects were asked to follow the procedure described below: Hold the softer central part of the container firmly between the thumb and index finger. Applying firm pressure, squeeze the liquid into a glass, then release the container. Repeat this procedure 5 times.
  • Suitable single-dose laminated containers which guarantee the physical and chemical stability of the solution they contain were also identified.
  • T4 solution 100 ⁇ g/mL was stored at 30°C/65% RH for 30 days
  • the process used is similar to the one previously described for the single-dose LDPE container.
  • one- component LDPE containers in sealed sachets proved to guarantee the physical and chemical stability of the formulation of T3 and T4.
  • Said formulation is used to prepare T4 doses of up to 200 ⁇ g, T3 up to 20 ⁇ g, and combinations of both active ingredients.
  • excipients such as ethanol and glycerol are used, the concentrations of which can range between 5 and 30% w/v for the former and 70 to 95% w/v for the latter, with water as required.
  • the T4 is solubilized in ethanol in a suitable dissolver, under continuous stirring at ambient temperature.
  • glycerol is added, and a homogenous, clear, colourless solution is obtained under gentle stirring at ambient temperature.
  • the solution is filtered (0.8 ⁇ ), and is then ready for filling a suitable primary container.
  • the Melt Flow Index or Melt Index is the index of fluidity of a molten polymer.
  • the prototypes are prepared on a laboratory scale, using an automatic pipette (Gilson P-1000) to fill disposable containers with 1.1 mL of the glycerol-ethanol solution previously described (prepared as described in example 1), after which the containers are sealed with a Pentaseal-lab benchtop sealing machine.
  • Table 9 lists the T4 content obtained during a period of three months after preparation, the T3 value and the sum of the impurities, excluding T3, found in the individual single-dose container during the experiment. The values relating to the condition considered most drastic for the product, i.e. 30°C/65% H, are recorded.
  • the single-dose LDPE container compared in absolute terms with the other materials selected and described, proved able to preserve the chemical quality of the product to a sufficient extent according to the parameters considered.
  • Stratified film with high gas and light barrier Polyester 12 ⁇ , Al 9 ⁇ , Polyethylene 50 ⁇ (values to be considered + 5-6%);
  • Oxygen permeability 0.1-0.2 cc/m 2 /day
  • the oxygen permeability was measured in accordance with ASTM Standard D-3985.
  • the water permeability was measured in accordance with ASTM
  • the prototypes are prepared on a laboratory scale, using an automatic pipette (Gilson P-1000) to fill disposable containers with 1.1 mL of the glycerol-ethanol solution previously described (prepared as described in example 1), after which the containers are sealed with a Pentaseal-lab benchtop sealing machine. Part of the batch is packaged in a hermetically sealed sachet of the type described above.
  • the sachets are then placed in suitable environmental test chambers, and immediately undergo a stability study under ICH conditions; the equipment used is calibrated and instantly monitored for correct operation.
  • the samples stored in the protective sachet demonstrate a greater ethanol containment capacity than the unprotected samples.
  • the product is industrialized by preparing 50 liters of said formulation (as described in example 1). A rotor dissolver of suitable capacity and a semi-automatic Comas Pentafill SA machine for filling single-dose containers (15 strokes per minute) is used. Part of the batch is packaged in a hermetically sealed sachet of the type described, while the remainder is kept in cardboard boxes but not hermetically protected.
  • the samples after being placed in suitable environmental test chambers, immediately undergo a stability study under ICH conditions; the equipment used is calibrated and instantly monitored for correct operation.
  • Table 10 lists the residual ethanol values in the individual single- dose container in the sealed sachet, and without the sachet. The values relating to the ICH condition 30°C/65% H are recorded.
  • the single-dose LDPE container in the sealed sachet offered the best performance after only three months of the experiment. A year after the start of the experiment, the percentage difference in the ethanol present in the formulation is measurable at around 24%.
  • Examples 1 and 2 demonstrate the efficacy of the 1 mL single-dose LDPE container stored in a hermetically sealed sachet (PET/Al/PE).
  • T4 Solution 25 /mL in single-dose one-component LDPE container contained in hermetically sealed sachet (PET/Al/PE)
  • T4 Solution 50 /mL in single-dose one-component LDPE container contained in hermetically sealed sachet (PET/Al/PE)
  • T4 Solution 75 /mL in single-dose one-component LDPE container contained in hermetically sealed sachet (PET/Al/PE)
  • T4 Solution 100 /mL in single-dose one-component LDPE container contained in hermetically sealed sachet (PET/Al/PE)
  • Samples prepared as described in example 2/D are stored in hermetically sealed sachets consisting of:
  • Samples prepared as described in example 2/D are stored in hermetically sealed sachets consisting of:
  • the prototypes are prepared on a laboratory scale, using an automatic pipette (Gilson P-1000) to fill 5 -layer laminated disposable containers with 1.1 mL of the glycerol-ethanol solution previously disclosed (prepared as described in example 1), after which the containers are sealed with a manual laboratory sealing machine.
  • an automatic pipette Glass P-1000
  • the container is made in a specific mould by a blowing technique; it is transparent (but can be opacified to protect it from light), has a wall approx. 600 ⁇ thick, and consists of laminated layers of the following materials: LDPE, EVOH, NF 408 adhesive (PE and maleic anhydride); EVOH performs the main function of a barrier to gas permeation. Specifically, PE is Purell PE 1840 H; EVOH is EVAL 101 B.
  • the samples prepared were stored at the temperature of 30°C and 65% relative humidity for 30 days.
  • the same Table compares the data obtained from samples stored in single-dose laminated containers with PP but without EVOH, and in single-dose LDPE containers with and without protective sachet. The values determined are expressed as percentages, and shown in Table 15.
  • the single-dose laminated container containing PE-EVOH keeps the product in high-quality conditions, and the values measured (impurities and ethanol content) are similar to those obtained with a single-dose one-component LDPE container stored in a hermetically sealed sachet.
  • 1.1 mL disposable laminated containers are filled with the glycerol- ethanol solution already described (prepared as shown in example 1), using an automatic pipette (Gilson P-1000).
  • Said empty single-dose container is made in a special mould. It is obtained by joining 2 symmetrical half-shells generated by a blowing technique similar to the one used to make blister packs. After volumetric filling it is sealed by a manual laboratory sealing machine.
  • the wall of the single-dose container is approx. 400 ⁇ thick, and consists of layers of the following materials: PE, EVOH, PP, ACLA ® .
  • the samples prepared were stored at the temperature of 30°C and 65% relative humidity for 30 days.
  • the same Table compares the data obtained from samples stored in single-dose LDPE containers with and without protective sachet. The values determined are expressed as percentages, and shown in Table 16.
  • the single-dose laminated container containing PE-EVOH-PP-ACLAR ® only 400 ⁇ thick keeps the product in good quality conditions, and the values measured (impurities and ethanol content) are not very different from those obtained with a single-dose one-component LDPE container stored in a hermetically sealed sachet.
  • 1.1 mL disposable laminated containers are filled with the glycerol- ethanol solution already disclosed (prepared as described in example 1), using an automatic pipette (Gilson P-1000).
  • Said empty single-dose container is made in a special mould. It is obtained by joining 2 symmetrical half-shells generated by a blowing technique similar to the one used to make blister packs. After volumetric filling it is sealed by a manual laboratory sealing machine.
  • the wall of the single-dose container is approx. 300 ⁇ thick, and consists of layers of the following materials: PVC, PVDC, PE.
  • the single-dose laminated container containing PVC, PVDC, PE only 300 ⁇ thick keeps the product in good quality conditions, and the values measured (impurities and ethanol content) are not very different from those obtained with a single-dose one-component LDPE container stored in a hermetically sealed sachet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Packages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a single-dose formulation for oral use of the thyroid hormones triiodothyronine or liothyronine (T3) and tetraiodothyronine or thyroxine (T4) in water-alcohol solution, which is physically and chemically stable, protected against accidental or microbiological contamination, in a container for pharmaceutical use which is squeezable and impermeable to the evaporation of the volatile substances it contains, and the corresponding means for implementing it.

Description

SINGLE-DOSE PHARMACEUTICAL PREPARATION OF THYROID
HORMONES T3 AND/OR T4
The present invention relates to a pharmaceutical preparation of thyroid hormones T3 and T4. Specifically, the invention relates to a pharmaceutical preparation of thyroid hormones T3 and T4 in water-alcohol solution, suitable for oral administration and characterised by high physical, chemical and microbiological stability. The invention also relates to the use of said pharmaceutical preparation in the treatment of disorders caused by hormone T3 and/or T4 deficiency.
BACKGROUND TO THE INVENTION
The thyroid hormones triiodothyronine or liothyronine (T3) and tetraiodothyronine or thyroxine (T4) are secreted by the follicular cells of the thyroid gland in response to the pituitary-gland hormone TSH, the production of which is regulated in turn by the hypothalamic hormone T H. The secretion of thyroid hormones follows a circadian rhythm; the highest levels of T3 and T4 are reached during the night and the early hours of the morning.
T3 and T4 are essential for the normal body growth of children and for the maturation of the various apparatuses, especially the skeleton, and regulate metabolic activity in the adult, influencing the function of every organ and tissue. In particular, T3 and T4 increase oxygen consumption at rest, raising the basal metabolism, the body temperature and the daily calorie requirement. They regulate carbohydrate metabolism, promoting glycogenolysis and gluconeogenesis, and increase the activity of the enzymes involved in glucose oxidation. The thyroid hormones are involved in lipolysis and lipogenesis, regulate protein synthesis, exercising a trophic effect on the muscle, and affect the cardiovascular system.
Thyroid hormones are essential to the cardiac function: they increase myocardial contractility (positive inotropic effect), increase the heart rate (positive chronotropic effect) and increase venous return to the heart.
In general, the effect of the thyroid hormones is mainly anabolic at low doses, whereas they have a catabolic action at high doses. In situations of physiological deficiency of thyroid hormones, as in the case of primary and secondary hypothyroidism, a treatment based on T3 and/or T4 is required, administered as such or in the form of sodium salts or hydrates.
Treatment with thyroid hormones continues throughout the patient's life, and the posology (dose and frequency of administration) is customized according to the patient's response. The initial dose of T3 and T4 is usually low. The dose is then gradually increased until the clinical evaluation and laboratory tests indicate an optimum response. Selecting the dose is a critical aspect: an under-dose leads to a poor response, while an excessive dose can produce toxic symptoms of hyperthyroidism such as tachycardia, sweating, weight loss, nervousness, diarrhoea, bone resorption due to activation of the osteoclasts, and heart problems.
It is therefore important for patients to be able to count on reliable formulations in terms of dose accuracy.
Oral pharmaceutical forms of T3 and T4 hormones are on the market in solid form (regular tablets and soft gelatin capsules) and in liquid oral form in drops. This last pharmaceutical form makes the hormones immediately available for gastrointestinal absorption, and usually consists of a solution in a single multi-dose glass container with a dropper. The use of the dropper makes it difficult to measure accurately the volume of solution dispensed, and therefore the dose administered. If a T4 solution with a concentration of 100 μg/mL is used, for example, T4 doses of between 3.5 and 200 μg may be administered. Assuming that each drop (approx. 35 μΐ.) contains 3.5 μg of T4, the administration of the maximum dose of 200 μg requires no less than 57 drops to be dispensed (2 mL). Moreover, the volume of the drops dispensed is not precisely replicable. The use of a dropper may therefore not guarantee the necessary dose accuracy, which is provided by other forms of administration such as tablets or soft capsules available in a variety of doses to allow optimum individual treatments.
The precarious accuracy of the dose represents a particularly important problem for drugs with a small therapeutic window such as thyroid hormones, especially in specific patient populations (children and the elderly). In the case of liquid pharmaceutical forms of T3 and/or T4, it is therefore evident that the availability on the market of single-dose pharmaceutical packs meets a clear therapeutic need.
In the liquid pharmaceutical forms (solutions, emulsions and suspensions) and semi-solid forms (creams, ointments and pastes), formulation ingredients for pharmaceutical use with high vapor pressure in general, such as alcohols, or inert gases, such as nitrogen, can act as solvents of the active ingredients present in the finished product or as preservatives, and can also, in synergy with other ingredients present in the pharmaceutical form, promote the physical and chemical stability of the finished product.
Volatile organic solvents such as ethanol are used to facilitate the dissolution of hormones T3 and/or T4. Adequate containment of volatile substances is necessary to guarantee the physical and chemical stability of the product. Evaporation of said substances from the formulation through the primary packaging material must be prevented, to avoid a gradual reduction in their concentration over time.
STATE OF THE ART
Patent application WO2010/086030, filed by the applicant, discloses a single-dose squeezable container for solutions of T3/T4 hormones, which is made of plastic with a Young's modulus of between 10 and 80 MPa, and in particular of a mixture of polyethylene or polypropylene with ethylene vinyl acetate. However, it has been observed that although said container presents optimum squeezability characteristics which ensure that the solution is completely emptied, it is unable to preserve the chemical and physical stability of the water-alcohol solutions of hormones T3/T4 it contains, causing a loss of alcohol solvent and increasing the quantity of impurities present in it during storage.
The purpose of the present invention is therefore to overcome the drawbacks associated with the prior art, in particular the chemical and physical instability of water-alcohol solutions of hormone T3/T4 stored in the containers described in WO2010/086030, while maintaining the convenience and accuracy of dose and administration offered by single-dose squeezable containers.
DESCRIPTION OF THE INVENTION
The present invention relates to a single-dose pharmaceutical preparation of thyroid hormones T3 and T4 suitable for oral administration, in ready-for-use packaging consisting of a container prefilled with a water-alcohol solution of hormone T3 and/or T4, said container being selected from:
(a) one-component LDPE plastic container, squeezable by manual compression, with a Young's modulus of between 10 and 200 MPa, placed in a sealed sachet consisting of a film made up of multiple layers of materials selected from the following: polyethylene, aluminium, polyethylene terephthalate, ionomer resins, paper, ethylene vinyl alcohol copolymer resins, polypropylene, and fluorinated-chlorinated resins;
(b) multi-component laminated plastic container with a thickness of between 200 and 700 μηι, squeezable by manual compression, having a Young's modulus of between 10 and 200 MPa and characterised by multiple layers of plastics suitably selected from polyethylene, ethylene vinyl alcohol copolymer resins, polyvinyl chloride, polyvinylidene chloride, polyvinyl acetate, fluorinated-chlorinated resins, ionomer resins, cyclic olefin copolymers, polyamide, polystyrene, polycarbonate, laminated metals, and in particular aluminium bonded to plastics.
In one embodiment of container (a), the sachet consists of a film made of several layers of materials according to the following combinations: polyethylene, aluminium and polyester; polyethylene, aluminium and paper; ionomer resins, aluminium and paper. The sachet also presents oxygen and water vapor permeability preferably between 0.1 and 0.2 cc/m2/day.
The water-alcohol solution can contain 1 to 20 g of thyroid hormone T3 and/or 12.5 to 200 g of thyroid hormone T4, ethyl alcohol in quantities preferably ranging between 5 and 30% w/v, glycerol in quantities preferably ranging between 70 and 95% w/v, and water.
At the end of the stability period, the pharmaceutical preparation according to the invention contains not less than 95% of the initial ethanol concentration, a T3 and/or T4 content of not less than 95% of the initial concentration, and total impurities (excluding impurity T3 in the single-dose T4 container) < 2.5% of the initial concentration of active ingredient.
Moreover, the pharmaceutical preparation according to the invention, due to its characteristics, guarantees the absence of microbiological contamination, with TAMC (total aerobic microbial count) values < 100 CFU/g, TYMC (total yeast and mould count) values < 10 CFU/g, and absence of E. coli, thus being practical to use and not liable to accidental contamination.
The pharmaceutical preparation according to the invention is conveniently used to treat disorders associated with thyroid hormone T3 and/or T4 deficiency. A further aspect of the invention therefore relates to the use of a water- alcohol solution of thyroid hormone T3 and/or T4 in a container as described above, to prepare a medicament for oral administration in the treatment of disorders associated with thyroid hormone T3 and/or T4 deficiency.
DETAILED DESCRIPTION OF THE INVENTION
In the field of liquid oral formulations of hormones T3/T4, the choice of packaging material is important to allow the correct volume of solution to be delivered easy and precisely.
In order to be easily squeezable and ensure complete delivery of its contents, the container must be soft and malleable. This state is usually achieved with the use of low-density polyethylene, polypropylene and sometimes with the addition of suitable "softening" agents such as EVA, which produce "loose" crosslinking. Squeezable containers are characterised by a plastic material having a sufficiently low Young's modulus. The best results have been obtained with plastics characterised by a Young's modulus of less than 200 MPa. It has been demonstrated that when plastic containers with such a Young's modulus are used, the contents are almost completely extracted by a single manual compression.
The Young's modulus according to the purposes of the present invention is determined by: (1) generating a stress strain curve by subjecting specimens with the dimensions established by the applicable standard UNI EN ISO 527-1 (16.5 * 1.0 cm) to tension at the rate of 5 mm/min and (2) determining the slope of the initial, linear portion of the stress strain curve in which the Hook's law E = σ/ε is applicable, wherein:
σ = F/A where F is the force exerted on the specimen under tension and A is the cross-sectional area through which the force is applied;
ε = ΔΙ/1 where Δ1 is the amount by which the length of the object changes and 1 is the original length of the object. Plastics with such a Young's modulus are obtainable by injection molding or blowing.
Suitable pharmaceutical-grade plastics can be polyethylene (PE), ethylene vinyl alcohol copolymer resins (EVOH), polyvinyl chloride (PVC), polyvinylidene chloride (PVdC), polyvinyl acetate (PVA), fluorinated- chlorinated resins, ionomer resins, cyclic olefin copolymers (COC), polyamides (PA), polystyrene (PS), polycarbonate (PC), laminated metals such as aluminium bonded to plastics, blends of the materials listed above in variable percentages, or stratifications of the above-mentioned materials of variable thickness. However, although many of these materials produce containers that are easily squeezed and have low Young's modulus values, they have proved inadequate to guarantee the necessary physical and chemical stability of said formulation.
The best results have been obtained with an LDPE container packaged in a sachet made of non-breathable material as secondary packaging.
In terms of ethanol content, the physical stability of the T4 water-alcohol solution (100 μg/mL) in said single-dose container has proved significantly better than the stability of the same solution in single-dose primary packaging consisting of an EVA-PE blend (50%-50%, according to WO2010/086030) - see Table 1. The experiment was conducted by placing the samples at 40°C/75% H for 7 days. The values are expressed as a percentage of the initial ethanol content. Table 1
100 μg/mL T4 solution in single-dose containers stored at 40°C/75% H for 7 days
Figure imgf000009_0001
The T4 preparation to which the present invention relates proved, in terms of total impurity content, more stable than the solution stored in single- dose primary packaging made of an EVA-PE blend (50%-50%) (Table 2).
The experiment was conducted by storing the samples at 50°C for ten days. The values are expressed as percentages of the initial active ingredient content.
Table 2
100 μg/mL T4 solution in single-dose containers stored at 50°C for 10 days
Figure imgf000009_0002
The T4 preparation according to the invention in single-dose packaging proved more chemically stable than similar formulations in multi-dose amber glass bottles present on the market.
Table 3 compares the values of the impurities after storage under ICH conditions at 25°C/60% RH for 6 months. The values are expressed as percentages of the active ingredient content.
Table 3
100 μg/mL T4 solution stored at 25°C/60% RH for 6 months
Figure imgf000010_0001
The chemical stability of the T4 solution, stored in packaging according to the present invention, proved better than that of the same solution stored in multi-dose amber bottles. Table 4 compares the values of the impurities in samples stored under ICH conditions at 25°C/60% RH for 6 months. The values are expressed as percentages of the initial active ingredient content.
Table 4
100 μg/mL T4 solution stored at 25°C/60% RH for 6 months
Figure imgf000010_0002
In terms of ethanol content and total impurities, the physical and chemical stability of the water-alcohol solution of T4 (100 μg/mL) in a single- dose LDPE container in hermetically sealed sachet proved even greater than that packaged in a single-dose container made of SURLYN® resins (code 1652) used for packaging in various fields, such as the food and cosmetic fields (Table 5). Table 5
Stability of the T4 100 μg/mL solution stored at 30°C/65% H
Figure imgf000011_0001
Similar results were obtained with other SURLYN resins , such as SURLYN® code 1802 and SURLYN® code 1702.
The extractability of the water-alcohol T4 solution from the single- dose LDPE container containing 1.1 mL of solution was evaluated by means of a squeezability test based on successive squeezes to demonstrate the complete, reproducible release of the expected volume of solution, namely 1.0 mL. The test involved a representative population of 60 subjects, matched for gender and age, divided into three groups consisting of 10 males and 10 females aged under 30 years, over 50 years or between 30 and 50 years. The subjects were asked to follow the procedure described below: Hold the softer central part of the container firmly between the thumb and index finger. Applying firm pressure, squeeze the liquid into a glass, then release the container. Repeat this procedure 5 times. The weight of the volume squeezed out by each squeeze was determined with an analytical balance. The weight was than converted to the corresponding volume using the density value (d) of the solution determined experimentally at ambient temperature (d= 1 , 1 145 g/mL).
The mean values of the volumes squeezed out are shown in Table 6, together with the standard deviation (SD), coefficient of variation (CV%) and 95% confidence interval (95% CI).
The results demonstrate that the volume of 1.0 mL of T4 solution is completely extracted from the containers if they are squeezed 3-4 times. This guarantees the administration of an accurate, reproducible dose to the patient. The volume extracted does not exceed the nominal value of 1 mL if the container is squeezed further.
Table 6
Extractability of T4 solution from single-dose LDPE containers
Figure imgf000012_0001
Similar results were obtained with water-alcohol solutions of T3.
Suitable single-dose laminated containers which guarantee the physical and chemical stability of the solution they contain were also identified. The following single-dose laminated containers, filled with the T4 solution (100 μg/mL) described in detail in Example 1 , were selected.
1) PE-EVOH-PE70/PP200 ACLAR® laminated container, 400 μηι thick, made with a blowing technique
2) PE, EVOH, PP and ACLAR® laminated container, 400 μηι thick, made with a blowing technique
3) 5-layer laminated LDPE, EVOH container, adhesive NF408E, 600 μηι thick, made with a blowing technique. The containers were stored for 30 days at 30°C/65% H. The results of the physical and chemical stability tests on the T4 solution are set out in Table 7.
Table 7
100 μg/mL of T4 solution was stored at 30°C/65% RH for 30 days
Figure imgf000013_0001
As demonstrated by the results set out in Table 7, not all the laminated containers proved able to guarantee the chemical stability of the solution they contain. Specifically, the first laminated container does not guarantee suitable resistance to ethanol. The preparation of the second and third prototypes will be more particularly described in the examples below.
The extractability of the water-alcohol T4 solution from the single-dose 5-layer container containing 1.1 mL reported in table 7 (third single-dose container described) was evaluated by way of example.
The process used is similar to the one previously described for the single-dose LDPE container.
The mean values of the volumes squeezed out are shown in Table 8, together with the standard deviation (SD), coefficient of variation (CV%) and 95% confidence interval (95% CI).
The results demonstrate that a volume of 1.0 mL of T4 solution is completely extracted from the containers if they are squeezed 3-4 times. This guarantees the administration of an accurate, reproducible dose to the patient. The volume extracted does not exceed the nominal value of 1 mL if the container is squeezed further.
Table 8
Extractability of T4 solution from 5-layer single-dose containers
Figure imgf000014_0001
Similar results were obtained with water-alcohol solutions of T3.
As will be described in greater detail in the examples below, one- component LDPE containers in sealed sachets, and suitable multi-component laminated containers, proved to guarantee the physical and chemical stability of the formulation of T3 and T4.
EXAMPLE 1
Formulation and preparation of water-alcohol solution
Said formulation is used to prepare T4 doses of up to 200 μg, T3 up to 20 μg, and combinations of both active ingredients.
In the typical composition, excipients such as ethanol and glycerol are used, the concentrations of which can range between 5 and 30% w/v for the former and 70 to 95% w/v for the latter, with water as required.
One liter of water-alcohol solution containing 100 g/mL of T4 is prepared as follows, using the qualitative/quantitative composition listed below:
1) T4 0.105 g
2) ethanol (96%) 243 g
3) glycerol (85%) 861 g
The T4 is solubilized in ethanol in a suitable dissolver, under continuous stirring at ambient temperature. When a clear solution free of visible non-solubilized residues has been obtained, glycerol is added, and a homogenous, clear, colourless solution is obtained under gentle stirring at ambient temperature. The solution is filtered (0.8 μηι), and is then ready for filling a suitable primary container.
EXAMPLE 2
The solution, prepared as described in example 1 , is divided between four different one-component single-dose containers with a nominal volume of 1 mL characterised by different materials:
A) Squeezable single-dose PVC076 container (equal to PVC with a thickness of 60 μηι);
B) Squeezable single-dose COPO container (EMAA copolymer resin - MFI 9);
C) Squeezable sing le-dose SU LYN® 2 container (EMAA lonomer resin - partial Na & Zn salt and additives) - MFI 5;
D) Squeezable single-dose LDPE container (600 μηι thick).
The Melt Flow Index or Melt Index (MFI) is the index of fluidity of a molten polymer.
Filling of disposable containers
The prototypes are prepared on a laboratory scale, using an automatic pipette (Gilson P-1000) to fill disposable containers with 1.1 mL of the glycerol-ethanol solution previously described (prepared as described in example 1), after which the containers are sealed with a Pentaseal-lab benchtop sealing machine.
They are then placed in suitable environmental test chambers, and immediately undergo a stability study under ICH conditions; the equipment used is calibrated and instantly monitored for correct operation.
Table 9 below lists the T4 content obtained during a period of three months after preparation, the T3 value and the sum of the impurities, excluding T3, found in the individual single-dose container during the experiment. The values relating to the condition considered most drastic for the product, i.e. 30°C/65% H, are recorded.
Table 9
100 μg/mL T4 solution in single-dose containers stored at 30°C/65% RH
Figure imgf000017_0001
As will be seen, the single-dose LDPE container, compared in absolute terms with the other materials selected and described, proved able to preserve the chemical quality of the product to a sufficient extent according to the parameters considered.
EXAMPLE 3
Use of single-dose container with a nominal volume of 1 mL made of one-component LDPE plastic contained in a sealed sachet (PET/A1/PE). Characteristics of sachet:
Stratified film with high gas and light barrier: Polyester 12 μηι, Al 9 μηι, Polyethylene 50 μηι (values to be considered + 5-6%);
Oxygen permeability: 0.1-0.2 cc/m2/day
Water vapor permeability: 0.1-0.2 g/m2/day
The oxygen permeability was measured in accordance with ASTM Standard D-3985.
The water permeability was measured in accordance with ASTM
Standard E-398.
Filling of disposable containers
The prototypes are prepared on a laboratory scale, using an automatic pipette (Gilson P-1000) to fill disposable containers with 1.1 mL of the glycerol-ethanol solution previously described (prepared as described in example 1), after which the containers are sealed with a Pentaseal-lab benchtop sealing machine. Part of the batch is packaged in a hermetically sealed sachet of the type described above.
The sachets are then placed in suitable environmental test chambers, and immediately undergo a stability study under ICH conditions; the equipment used is calibrated and instantly monitored for correct operation.
The samples stored in the protective sachet demonstrate a greater ethanol containment capacity than the unprotected samples. The product is industrialized by preparing 50 liters of said formulation (as described in example 1). A rotor dissolver of suitable capacity and a semi-automatic Comas Pentafill SA machine for filling single-dose containers (15 strokes per minute) is used. Part of the batch is packaged in a hermetically sealed sachet of the type described, while the remainder is kept in cardboard boxes but not hermetically protected.
Again in this second case, the samples, after being placed in suitable environmental test chambers, immediately undergo a stability study under ICH conditions; the equipment used is calibrated and instantly monitored for correct operation.
Table 10 below lists the residual ethanol values in the individual single- dose container in the sealed sachet, and without the sachet. The values relating to the ICH condition 30°C/65% H are recorded.
Table 10
100 μg/mL T4 solution in single-dose containers with and without sachet, stored at 30°C/65% RH
Figure imgf000019_0001
As will be seen, the single-dose LDPE container in the sealed sachet offered the best performance after only three months of the experiment. A year after the start of the experiment, the percentage difference in the ethanol present in the formulation is measurable at around 24%.
Examples 1 and 2 demonstrate the efficacy of the 1 mL single-dose LDPE container stored in a hermetically sealed sachet (PET/Al/PE).
Similar results are obtained by making industrial batches of T4 as described in example 1 with different doses (25, 50 and 75 μg of T4), stored under ICH conditions at 30°C/65% RH and 25°C/60% RH for 12-18 months. The preparations gave excellent results in terms of physical, chemical and microbiological stability (see Tables 1 1 , 12, 13 and 14).
Table 11
T4 Solution (25 /mL) in single-dose one-component LDPE container contained in hermetically sealed sachet (PET/Al/PE)
Figure imgf000021_0001
(continued)
Figure imgf000022_0001
LOQ: Limit of quantitation
Table 12
T4 Solution (50 /mL) in single-dose one-component LDPE container contained in hermetically sealed sachet (PET/Al/PE)
Product 30°C ± 2°C / 65% ± 5% R.H. 25°C ± 2°C / 60% ± 5% R.H
Analysis
specifications 3 m 6 m 9 m 12 m 3 m 6 m 9 m 12 m
Clear, colourless
Appearance or pale yellow Conforming Conforming Conforming Conforming Conforming Conforming Conforming Conforming Conforming
solution
Relative 1.107 ±0.012
107 1.110 1.109 1.109 1.108 1.108 1.110 1.109 1.110
density g/ 3 1.
cm
T4
Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive
identification
95.0-105.0% of
T4 content 102.9 101.2 99.5 98.2 98.1 101.5 101.2 100.2 99.7
theoretical value
Impurities/ Release: Stability:
Degradation
products:
- T3 < 0.2% < 2.5% <LOQ 1.1 1.8 2.0 2.4 0.5 1.2 1.3 1.5
- T2 < 0.1% < 0.5% <LOQ <LOQ <LOQ <LOQ 0.1 <LOQ <LOQ <LOQ 0.15
Triac < 0.25% < 1.0% <LOQ <LOQ 0.4 0.6 0.75 <LOQ <LOQ <LOQ 0.45
Tetrac
< 0.3% < 1.0% <LOQ <LOQ <LOQ <LOQ 0.35 <LOQ <LOQ <LOQ 0.4
- Single
unknown 0.2 0.2 0.3 <LOQ <LOQ <LOQ 0.2
impurities < 0.05% < 0.5% <LOQ <LOQ
Total
impurities
≠T3 < 1.0°, < 2.5% 0.7 0.7 1.0 1.3 1.5 0.7 0.7 0.7 1.2
(continued
Figure imgf000024_0001
LOQ: Limit of quantitation
Table 13
T4 Solution (75 /mL) in single-dose one-component LDPE container contained in hermetically sealed sachet (PET/Al/PE)
Figure imgf000025_0001
(continued
Figure imgf000026_0001
Table 14
T4 Solution (100 /mL) in single-dose one-component LDPE container contained in hermetically sealed sachet (PET/Al/PE)
Figure imgf000027_0001
(continued
Figure imgf000028_0001
EXAMPLE 4
Samples prepared as described in example 2/D are stored in hermetically sealed sachets consisting of:
- triple heat-sealable stratified film made of Polythene 36 μηι, Al 8 μηι, Paper 51 μηι (single film thicknesses to be considered + 5-6%).
In this case too, after six months' storage under conditions of 30°C-60% H, the ethanol content in the sample (97.7%), together with the remaining parameters (T4 content: 96.89%; T3 content: 1.05%; sum total of impurities excluding T3: 2.06%), remained at adequate levels.
EXAMPLE 5
Samples prepared as described in example 2/D are stored in hermetically sealed sachets consisting of:
- triple heat-sealable stratified film made of low-density SURLYN® resin 23.5 μηι, Al 12 μηι, Paper 51 μηι (single film thicknesses to be considered + 5-6%).
In this case too, after six months' storage under conditions of 30°C-60% RH, the ethanol content in the sample (96.30%), together with the remaining parameters (T4 content: 97.48%; T3 content: 1.06%; sum total of impurities excluding T3: 1.46%), remained at adequate levels.
Filling of disposable containers made of laminated material without protective sachet
EXAMPLE 6
The prototypes are prepared on a laboratory scale, using an automatic pipette (Gilson P-1000) to fill 5 -layer laminated disposable containers with 1.1 mL of the glycerol-ethanol solution previously disclosed (prepared as described in example 1), after which the containers are sealed with a manual laboratory sealing machine.
The container is made in a specific mould by a blowing technique; it is transparent (but can be opacified to protect it from light), has a wall approx. 600 μηι thick, and consists of laminated layers of the following materials: LDPE, EVOH, NF 408 adhesive (PE and maleic anhydride); EVOH performs the main function of a barrier to gas permeation. Specifically, PE is Purell PE 1840 H; EVOH is EVAL 101 B.
The samples prepared were stored at the temperature of 30°C and 65% relative humidity for 30 days. The same Table compares the data obtained from samples stored in single-dose laminated containers with PP but without EVOH, and in single-dose LDPE containers with and without protective sachet. The values determined are expressed as percentages, and shown in Table 15.
Table 15
100 μg/mL T4 solution in single-dose containers stored at 30°C/65% H for 30 days
Figure imgf000030_0001
As will be seen, the single-dose laminated container containing PE-EVOH keeps the product in high-quality conditions, and the values measured (impurities and ethanol content) are similar to those obtained with a single-dose one-component LDPE container stored in a hermetically sealed sachet.
EXAMPLE 7
1.1 mL disposable laminated containers are filled with the glycerol- ethanol solution already described (prepared as shown in example 1), using an automatic pipette (Gilson P-1000).
Said empty single-dose container is made in a special mould. It is obtained by joining 2 symmetrical half-shells generated by a blowing technique similar to the one used to make blister packs. After volumetric filling it is sealed by a manual laboratory sealing machine.
The wall of the single-dose container is approx. 400 μηι thick, and consists of layers of the following materials: PE, EVOH, PP, ACLA ®.
The samples prepared were stored at the temperature of 30°C and 65% relative humidity for 30 days. The same Table compares the data obtained from samples stored in single-dose LDPE containers with and without protective sachet. The values determined are expressed as percentages, and shown in Table 16.
Table 16
100 μg/mL T4 solution in single-dose containers stored at 30°C/65% RH for 30 days
Total impurities
Ethanol (%)
(%)
Prototype
T=30 T=30
T=0 T=0
days days
Laminated PE-EVOH-PP-Aclar single-
96.4 1.30 dose container
Single-layer LDPE single-dose container
99.8 83.0 0.70 3.92 without protective sachet
Single-layer LDPE single-dose container
99.0 0.80 with protective sachet As will be seen, the single-dose laminated container containing PE-EVOH-PP-ACLAR® only 400 μηι thick keeps the product in good quality conditions, and the values measured (impurities and ethanol content) are not very different from those obtained with a single-dose one-component LDPE container stored in a hermetically sealed sachet.
The sample subjected to said conditions for 6 months proved stable in terms of general quality. The percentage values found are set out below.
- T4 content: 97.56%;
Total impurities: 2.44%;
- Ethanol content: 97%.
EXAMPLE 8
1.1 mL disposable laminated containers are filled with the glycerol- ethanol solution already disclosed (prepared as described in example 1), using an automatic pipette (Gilson P-1000).
Said empty single-dose container is made in a special mould. It is obtained by joining 2 symmetrical half-shells generated by a blowing technique similar to the one used to make blister packs. After volumetric filling it is sealed by a manual laboratory sealing machine.
The wall of the single-dose container is approx. 300 μηι thick, and consists of layers of the following materials: PVC, PVDC, PE.
The samples prepared were stored at the temperature of 30°C and 65% relative humidity for 30 days. The same Table compares the data obtained from samples stored in single-dose LDPE containers with and without protective sachet. The values determined are expressed as percentages, and shown in Table 17. Table 17
100 μg/mL T4 solution in single-dose containers stored at 30°C/65% H for 30 days
Figure imgf000033_0001
As will be seen, the single-dose laminated container containing PVC, PVDC, PE only 300 μηι thick keeps the product in good quality conditions, and the values measured (impurities and ethanol content) are not very different from those obtained with a single-dose one-component LDPE container stored in a hermetically sealed sachet.
The sample subjected to said conditions for 6 months proved stable of general quality. The percentage values found are set out below.
- T4 content: 97.54%;
- Total impurities: 2.46%;
- Ethanol content: 98%.

Claims

1. A single-dose pharmaceutical preparation of T3 and T4 thyroid hormones suitable for oral administration, in ready-to-use packaging consisting of a container pre-filled with a water-alcohol solution of hormone T3 and/or T4, said container being selected from:
(a) a one-component LDPE plastic container, squeezable by hand-compression and having a Young's modulus of between 10 and 200 MPa, placed in a sealed sachet consisting of a laminated film made of materials selected from the following: polyethylene, aluminium, polyethylene terephthalate, ionomer resins, ethylene vinyl alcohol copolymer resins, polypropylene, and fluorinated-chlorinated resins;
(b) a multi-component laminated plastic container having a thickness of between 200 and 700 μηι, squeezable by hand-compression and having a Young's modulus of between 10 and 200 MPa, said container consisting of multiple layers of plastic materials selected from polyethylene, ethylene vinyl alcohol copolymer resins, polyvinyl chloride, polyvinylidene chloride, polyvinyl acetate, fluorinated-chlorinated resins, ionomer resins, cyclic olefin copolymers, polyamide, polystyrene, polycarbonate and laminated metals.
2. Pharmaceutical preparation according to claim 1 , wherein said sachet consists of a laminated film made of different materials, in the following combinations: polyethylene, aluminium and polyester; polyethylene, aluminium and paper; ionomer resins, aluminium and paper.
3. A pharmaceutical preparation according to claims 1 and 2, wherein said sachet exhibits oxygen and water-vapor permeability ranging from 0.1 to
0.2 cc/m2/day.
4. A pharmaceutical preparation according to claims 1-3, wherein the water-alcohol solution contains 1 to 20 g T3 thyroid hormone and/or 12.5 to 200 g T4 thyroid hormone.
5. A pharmaceutical preparation according to claim 4, wherein said water-alcohol solution also contains ethyl alcohol, glycerol and water.
6. A pharmaceutical preparation according to claim 5, wherein said water-alcohol solution contains 5 to 30% w/v ethyl alcohol and 70 to 95% w/v glycerol.
7. A pharmaceutical preparation according to claims 1-6, for use in the treatment of diseases associated with T3 and/or T4 hormone deficiency.
8. The use of a water- alcohol solution of T3 and/or T4 thyroid hormone in a container according to claims 1-6, for the preparation of a medicament for oral administration to be used in the treatment of diseases associated with T3 and/or T4 hormone deficiency.
PCT/EP2012/072482 2011-11-14 2012-11-13 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4 WO2013072304A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US13/814,770 US20140179785A1 (en) 2011-11-14 2012-11-13 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4
DK12798182.7T DK2790638T3 (en) 2011-11-14 2012-11-13 PHARMACEUTICAL SINGLE DOSAGE PREPARATION OF THYROIDA HORMONES T3 AND / OR T4
CA2853880A CA2853880C (en) 2011-11-14 2012-11-13 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4
ES12798182.7T ES2621009T3 (en) 2011-11-14 2012-11-13 Pharmaceutical unit dosage of thyroid hormones T3 and / or T4
EP16154717.9A EP3056187B2 (en) 2011-11-14 2012-11-13 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4
PL16154717.9T PL3056187T5 (en) 2011-11-14 2012-11-13 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4
EP12798182.7A EP2790638B1 (en) 2011-11-14 2012-11-13 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4
CN201280055960.7A CN103987358B (en) 2011-11-14 2012-11-13 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4
RU2014119151A RU2688430C2 (en) 2011-11-14 2012-11-13 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4
HK15101283.7A HK1200692A1 (en) 2011-11-14 2015-02-05 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4 t3 / t4

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002066A ITMI20112066A1 (en) 2011-11-14 2011-11-14 SINGLE-DOSE ORAL PHARMACEUTICAL PREPARATION OF THYROID ORMONS T3 AND T4
ITMI2011A002066 2011-11-14

Publications (1)

Publication Number Publication Date
WO2013072304A1 true WO2013072304A1 (en) 2013-05-23

Family

ID=45315902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/072482 WO2013072304A1 (en) 2011-11-14 2012-11-13 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4

Country Status (14)

Country Link
US (1) US20140179785A1 (en)
EP (2) EP2790638B1 (en)
CN (2) CN103987358B (en)
CA (1) CA2853880C (en)
DK (2) DK2790638T3 (en)
ES (2) ES2698521T5 (en)
FI (1) FI3056187T4 (en)
HK (1) HK1200692A1 (en)
HU (1) HUE033305T2 (en)
IT (1) ITMI20112066A1 (en)
PL (2) PL2790638T3 (en)
PT (2) PT3056187T (en)
RU (2) RU2688430C2 (en)
WO (1) WO2013072304A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013017917A1 (en) * 2013-10-26 2015-04-30 Michael Raschke L-Thyrogal
EP3311844A1 (en) 2016-10-18 2018-04-25 Altergon S.A. High-stability packaged solutions of t4 thyroid hormone
IT201900003013A1 (en) 2019-03-01 2020-09-01 Altergon Sa Administration regimen of T4 thyroid hormone compositions with high oral absorption
US11241382B2 (en) 2019-03-01 2022-02-08 Altergon Sa Administration regimen of compositions of T4 thyroid hormone with high oral absorption
IT202100020105A1 (en) 2021-07-28 2023-01-28 Altergon Sa Use of T4 thyroid hormone in a highly versatile treatment in patients taking proton pump inhibitors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022221480A1 (en) * 2021-04-15 2022-10-20 Vertice Pharma Llc Stable liquid oral dosage forms of liothyronine
EP4295836A1 (en) * 2022-06-22 2023-12-27 Labomed Pharmaceutical Company S.A. Sachet comprising a liquid suspension of a sevelamer salt
CN115645361B (en) * 2022-09-30 2023-11-21 天津市眼科医院 Ophthalmic preparation for enhancing biomechanical property of cornea and application of T3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128920A (en) * 1964-04-14 figure
EP1291021A2 (en) * 2001-07-02 2003-03-12 Altergon S.A. Pharmaceutical formulations for thyroid hormones
WO2010086030A1 (en) 2009-01-30 2010-08-05 Altergon S.A. Container for pharmaceutical use for the quantitative release of a single dose for oral administration of t3 and t4 thyroid hormones in solution

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602352D0 (en) * 1996-06-14 1996-06-14 Astra Ab Catheter package
UA80393C2 (en) * 2000-12-07 2007-09-25 Алтана Фарма Аг Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix
GB0316206D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
JP2008519147A (en) * 2004-11-08 2008-06-05 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Reinforced polyamide for food packaging and health care applications
KR20070100720A (en) 2004-12-27 2007-10-11 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions
CN1820782B (en) * 2005-02-17 2012-08-29 阿尔特贡股份公司 Thyroid hormone medicinal preparation and its preparing method
AU2006230557A1 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
RU2435811C2 (en) * 2006-05-01 2011-12-10 Нанопэк, Инк. Barrier coatings for films and structures
KR101039270B1 (en) * 2007-12-24 2011-06-07 제이더블유생명과학 주식회사 Multilayer Film For Medical Solution Container And A Container Comprising The Same
DE102008056123B4 (en) * 2008-11-06 2017-11-16 Klöckner Pentaplast Gmbh Multilayer film and blister packaging

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128920A (en) * 1964-04-14 figure
EP1291021A2 (en) * 2001-07-02 2003-03-12 Altergon S.A. Pharmaceutical formulations for thyroid hormones
WO2010086030A1 (en) 2009-01-30 2010-08-05 Altergon S.A. Container for pharmaceutical use for the quantitative release of a single dose for oral administration of t3 and t4 thyroid hormones in solution

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013017917A1 (en) * 2013-10-26 2015-04-30 Michael Raschke L-Thyrogal
RU2765547C2 (en) * 2016-10-18 2022-02-01 Альтергон Са Highly stable packaged solutions of the thyroid hormone t4
US11096913B2 (en) 2016-10-18 2021-08-24 Altergon Sa High-stability packaged solutions of T4 thyroid hormone
CN109789213A (en) * 2016-10-18 2019-05-21 阿尔特贡股份公司 The high stability of T4 thyroid hormone packs solution
US10537538B2 (en) 2016-10-18 2020-01-21 Altergon Sa High-stability packaged solutions of T4 thyroid hormone
EP3528847B1 (en) 2016-10-18 2020-07-22 Altergon SA High-stability packaged solutions of t4 thyroid hormone
CN109789213B (en) * 2016-10-18 2022-05-31 阿尔特贡股份公司 High stability packaging solution for T4 thyroid hormone
EP3311844A1 (en) 2016-10-18 2018-04-25 Altergon S.A. High-stability packaged solutions of t4 thyroid hormone
WO2018073209A1 (en) 2016-10-18 2018-04-26 Altergon Sa High-stability packaged solutions of t4 thyroid hormone
WO2020178074A1 (en) 2019-03-01 2020-09-10 Altergon S.A. Administration regimen of solutions of t4 thyroid hormone with high oral absorption
US11241382B2 (en) 2019-03-01 2022-02-08 Altergon Sa Administration regimen of compositions of T4 thyroid hormone with high oral absorption
IT201900003013A1 (en) 2019-03-01 2020-09-01 Altergon Sa Administration regimen of T4 thyroid hormone compositions with high oral absorption
EP4321214A2 (en) 2019-03-01 2024-02-14 Altergon S.a. Administration regimen of solutions of t4 thyroid hormone with high oral absorption
IT202100020105A1 (en) 2021-07-28 2023-01-28 Altergon Sa Use of T4 thyroid hormone in a highly versatile treatment in patients taking proton pump inhibitors
WO2023006841A1 (en) 2021-07-28 2023-02-02 Altergon S.A. Use of thyroid hormone t4 in a high versatility treatment in patients taking proton pump inhibitors

Also Published As

Publication number Publication date
PT2790638T (en) 2017-04-19
ITMI20112066A1 (en) 2013-05-15
CA2853880A1 (en) 2013-05-23
RU2014119151A (en) 2015-12-27
EP3056187A9 (en) 2016-11-23
ES2621009T3 (en) 2017-06-30
DK3056187T3 (en) 2018-12-10
PL2790638T3 (en) 2017-07-31
FI3056187T4 (en) 2023-09-22
ES2698521T5 (en) 2024-01-22
EP3056187A1 (en) 2016-08-17
CN107049929A (en) 2017-08-18
CN103987358B (en) 2017-04-26
RU2018140275A (en) 2019-01-18
EP3056187B1 (en) 2018-08-22
RU2018140275A3 (en) 2022-03-23
CN107049929B (en) 2020-08-04
DK3056187T4 (en) 2023-09-25
EP3056187B2 (en) 2023-08-30
PL3056187T5 (en) 2023-12-04
PL3056187T3 (en) 2019-02-28
RU2688430C2 (en) 2019-05-21
DK2790638T3 (en) 2017-04-03
HUE033305T2 (en) 2017-11-28
EP2790638A1 (en) 2014-10-22
ES2698521T3 (en) 2019-02-05
HK1200692A1 (en) 2015-08-14
EP2790638B1 (en) 2017-01-04
PT3056187T (en) 2018-11-28
CN103987358A (en) 2014-08-13
CA2853880C (en) 2019-12-10
US20140179785A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
DK3056187T3 (en) Single dose pharmaceutical formulation of thyroid hormones T3 and / or T4
US11096913B2 (en) High-stability packaged solutions of T4 thyroid hormone
US9746421B2 (en) Apparatuses, indicators, methods and kits with timed color change indication
US9364393B1 (en) Packaging system for liquid medications
US20100197790A1 (en) Container for pharmaceutical use for the quantitative release of a single dose for oral administration of t3 and t4 thyroid hormones in solution
DK2217275T3 (en) A pharmaceutical composition in the form of a solution for bowel cleansing, comprising a docusate, an osmotic laxative and a benzoate.
WO1991001710A1 (en) Liquid dispenser calibrated by body weight
Umoren et al. Chronic administration of the antiretroviral nevirapine increases body weight, food, and water intake in albino Wistar rats
WO2017077407A1 (en) Single package system for solid and liquid for reconstitution

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 13814770

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12798182

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2853880

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012798182

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012798182

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014119151

Country of ref document: RU

Kind code of ref document: A